Search results for "Modified Rankin Scale"

showing 10 items of 29 documents

Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis

2019

Aim: To identify factors that may predict and affect the risk of relapse in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Method: This was a retrospective study of an Italian cohort of patients with paediatric (≤18y) onset anti-NMDAR encephalitis. Results: Of the 62 children included (39 females; median age at onset 9y 10mo, range 1y 2mo–18y; onset between 2005 and 2018), 21 per cent relapsed (median two total events per relapsing patient, range 2–4). Time to first relapse was median 31.5 months (range 7–89mo). Severity at first relapse was lower than onset (median modified Rankin Scale [mRS] 3, range 2–4, vs median mRS 5, range 3–5; admission to intensive care unit: 0/10 vs 3/10…

Male030506 rehabilitationGastroenterologyCohort Studies0302 clinical medicineRetrospective StudieModified Rankin ScaleRecurrenceRisk FactorsChildrelapseAnti-N-Methyl-D-Aspartate Receptor EncephalitisHazard ratioItalyChild PreschoolCohortanti‐N‐methyl‐D‐aspartate receptor encephalitisFemale0305 other medical scienceEncephalitisHumanCohort studymedicine.medical_specialtyAdolescentSocio-culturaleanti-NMDAR antibodies03 medical and health sciencesanti-NMDARDevelopmental NeuroscienceInternal medicinemedicineAdolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Italy; Male; Recurrence; Retrospective Studies; Risk FactorsHumansPreschoolSurvival analysisRetrospective StudiesAutoimmune encephalitisbusiness.industryInfantRetrospective cohort studymedicine.diseaseanti-NMDAR antibodies autoimmune encephalitis anti‐N‐methyl‐D‐aspartate receptor encephalitisautoimmune encephalitisAnti-N-methyl-D-aspartate receptor encephalitis anti-NMDAR autoimmune encephalitis relapseAnti-N-Methyl-D-Aspartate Receptor EncephalitiPediatrics Perinatology and Child HealthNeurology (clinical)Cohort Studiebusiness030217 neurology & neurosurgery
researchProduct

The Riga East University Hospital Stroke Registry—An Analysis of 4915 Consecutive Patients with Acute Stroke

2021

Background and Objectives: A hospital-based stroke registry is a useful tool for systematic analyses of the epidemiology, clinical characteristics, and natural course of stroke. Analyses of stroke registry data can provide information that can be used by health services to improve the quality of care for patients with this disease. Materials and Methods: Data were collected from the Riga East University Hospital (REUH) Stroke Registry in order to evaluate the etiology, risk factors, clinical manifestations, treatment, functional outcomes, and other relevant data for acute stroke during the period 2016–2020. Results: During a five-year period, 4915 patients (3039 females and 1876 males) with…

MaleMedicine (General)medicine.medical_specialtythrombolysisLacunar strokeArticlequality improvementR5-920Modified Rankin ScaleRisk FactorsInternal medicineEpidemiologyAtrial FibrillationmedicineHumansRegistriescardiovascular diseasesStrokeCerebral HemorrhageIntracerebral hemorrhagebusiness.industryMortality ratestroke registryAtrial fibrillationGeneral Medicinemedicine.diseasestrokeHospitalsintracerebral hematomaTreatment Outcomestroke datatransient ischemic attackEtiologyFemalebusinessMedicina
researchProduct

Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

2018

In patients treated with intravenous thrombolysis (IVT), an unfavourable ‘non-office-hours effect’ on door-to-needle time (DNT) and clinical outcome has been suggested. This effect has been attributed to a number of factors, mostly related to either less efficient logistics or less (experienced) staffing during non-office hours (NH). These factors could result in longer DNTs and more protocol violations and thus in worse clinical outcome. On the other hand, one could also argue that the workload during NH is lower, which could result in less time delays in the various diagnostic processes and thus in better clinical outcome. Our hypothesis is that admission during NH has a negative effect o…

MaleTime delaysmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOutcome (game theory)Time-to-TreatmentCohort Studies03 medical and health sciences0302 clinical medicinePatient AdmissionModified Rankin ScaleIschaemic strokemedicineHumansThrombolytic Therapy030212 general & internal medicineStrokeAgedAged 80 and overbusiness.industryThrombolysisMiddle Agedmedicine.diseasestroke3. Good healthMechanical thrombectomyPsychiatry and Mental healthTreatment OutcomeEmergency medicineCohortPhysical therapySurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology, neurosurgery, and psychiatry
researchProduct

Factors contributing to sex differences in functional outcomes and participation after stroke.

2018

ObjectiveTo examine factors contributing to the sex differences in functional outcomes and participation restriction after stroke.MethodsIndividual participant data on long-term functional outcome or participation restriction (i.e., handicap) were obtained from 11 stroke incidence studies (1993–2014). Multivariable log-binomial regression was used to estimate the female:male relative risk (RR) of poor functional outcome (modified Rankin Scale score >2 or Barthel Index score <20) at 1 year (10 studies, n = 4,852) and 5 years (7 studies, n = 2,226). Multivariable linear regression was used to compare the mean difference (MD) in participation restriction by use of the London Handicap Sca…

Malebusiness.industryBarthel indexIndividual participant dataStroke severityStroke RehabilitationRecovery of Function030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineSex FactorsModified Rankin ScaleRisk FactorsRelative riskMedicineHumansFemaleNeurology (clinical)businessStroke incidenceStroke030217 neurology & neurosurgeryDemographyNeurology
researchProduct

Population-Based Validation of the iScore for Predicting Mortality and Early Functional Outcome in Ischemic Stroke Patients

2013

<b><i>Background:</i></b> We aimed to determine the accuracy of the iScore for predicting mortality and early disability following ischemic stroke in a French population-based study. <b><i>Methods:</i></b> All patients with acute ischemic stroke were identified among residents of the city of Dijon, France, between 2006 and 2011, using a population-based stroke registry. The 30-day iScore and 1-year iScore were calculated. A logistic regression model was used to assess the performance of the iScore for predicting both 30-day and 1-year mortality, and poor functional outcome at discharge (modified Rankin Scale score of 3-6). The discrimination a…

Malemedicine.medical_specialtyEpidemiologyPopulationPopulation basedLogistic regressionPredictive Value of TestsModified Rankin ScaleInternal medicineEpidemiologymedicineHumanseducationStrokeAgedAged 80 and overeducation.field_of_studybusiness.industrymedicine.diseaseStrokePredictive value of testsIschemic strokePhysical therapyFemaleFranceNeurology (clinical)businessNeuroepidemiology
researchProduct

Poststroke Disposition and Associated Factors in a Population-Based Study

2012

Background and Purpose— The organization of poststroke care will be a major challenge in coming years. We aimed to assess hospital disposition after stroke and its associated factors in clinical practice. Methods— All cases of stroke from 2006 to 2010 were identified from the population-based Stroke Registry of Dijon, France. Demographic features, risk factors, and prestroke treatments were recorded. Admission stroke severity was assessed using the National Institutes of Health Stroke Scale score. At discharge, we collected dementia, disability using the modified Rankin Scale, length of stay, and hospital disposition (home, rehabilitation, convalescent home, and nursing home). Multivariate…

Malemedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentPopulationPopulation03 medical and health sciences0302 clinical medicineRisk FactorsModified Rankin ScaleAcute careEpidemiologyAphasiamedicineHumansDementiaProspective Studies030212 general & internal medicineeducationStrokeAgedAged 80 and overAdvanced and Specialized Nursingeducation.field_of_studyMuscle WeaknessRehabilitationbusiness.industry[SCCO.NEUR]Cognitive science/NeuroscienceAge FactorsStroke RehabilitationAnticoagulantsRecovery of FunctionMiddle Agedmedicine.diseasePatient Discharge3. Good healthHospitalizationStrokeLogistic ModelsTreatment Outcome[ SCCO.NEUR ] Cognitive science/NeurosciencePhysical therapyFemaleFranceNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryStroke
researchProduct

Plasma myeloperoxidase levels in acute brain ischaemia and high grade carotid stenosis.

2020

Myeloperoxidase (MPO) is an important oxidative enzyme participating in different stages of cardiovascular disease and predicts prognosis. Little is known about its role in acute cerebrovascular events and carotid plaque vulnerability. In this study, the aim was to assess plasma MPO levels in acute stroke patients and their correlation to stroke severity and stroke outcome.Plasma MPO levels were assessed in patients presenting with acute brain ischaemia within 36 h of symptom onset (n = 144, mean age 64.7 ± 11.6 years, 67% men) and in patients with moderate-to-severe carotid stenosis undergoing carotid artery stenting (n = 51, mean age 66.3 ± 8.4 years, 75% men). Patients presenting with ac…

Malemedicine.medical_specialtyStroke severityDiseaseBrain Ischemia03 medical and health sciencesPlasma0302 clinical medicineModified Rankin ScaleInternal medicineIschaemic strokemedicineHumansIn patientCarotid Stenosiscardiovascular diseases030212 general & internal medicineStrokeAgedPeroxidasebiologybusiness.industryMiddle Agedmedicine.diseaseStrokeStenosisTreatment OutcomeNeurologyMyeloperoxidaseCardiologybiology.proteinFemaleNeurology (clinical)business030217 neurology & neurosurgeryEuropean journal of neurologyReferences
researchProduct

Health-related quality of life, anxiety and depression up to 12 months post-stroke: Influence of sex, age, stroke severity and atrial fibrillation - …

2021

Abstract Background Stroke can negatively impact the health-related quality of life (HRQoL). Anxiety or depression after stroke have been associated with poorer HRQoL, higher mortality and greater dependence in activities of daily living. We aimed to analyze HRQoL, anxiety and depressive symptoms in patients with and without atrial fibrillation (AF) up to 12 months post-stroke. Methods Find-AFRANDOMISED was a prospective, randomized multicenter study, which included 398 patients ≥60 years with acute cerebral ischemia. HRQoL data were collected using the 3-level EuroQol-5D (EQ-5D-3L) and Stroke Impact Scale (SIS-16). Anxiety and depressive symptoms were measured using the Hospital Anxiety an…

Malemedicine.medical_specialtyTime FactorsAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineSex FactorsQuality of lifeModified Rankin ScaleInternal medicineActivities of Daily LivingAtrial FibrillationmedicineHumanscardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective StudiesStrokeDepression (differential diagnoses)Agedbusiness.industryDepressionAge FactorsAtrial fibrillationmedicine.diseasehumanities3. Good healthClinical trialStrokePsychiatry and Mental healthClinical PsychologyQuality of LifeAnxietyFemalemedicine.symptombusiness030217 neurology & neurosurgeryJournal of psychosomatic research
researchProduct

Health-related quality of life in patients with poststroke epilepsy.

2017

Abstract Background Lesional epilepsy is an important long-term sequela of stroke. Data on health-related quality of life (HrQoL) in patients with poststroke epilepsy are limited. We investigated HrQoL in patients with epilepsy after ischemic stroke and identified independent HrQoL-determinants. Methods and patients All patients with acute ischemic stroke, who were permanent residents in the district Marburg-Biedenkopf (Hessia, Germany, reference population 240,000 inhabitants) were recruited within 12 months in the population-based Marburg Stroke Register (MARSTREG). Follow-up visits were performed after 6, 12, and 24 months, and patients who developed poststroke epilepsy were identified. …

Malemedicine.medical_specialtyVisual analogue scalePopulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineQuality of lifeModified Rankin ScaleSeizuresInternal medicineGermanySurveys and QuestionnairesmedicineHumans030212 general & internal medicineeducationStrokeDepression (differential diagnoses)FatigueAgedPain Measurementeducation.field_of_studyEpilepsybusiness.industryDepressionStroke RehabilitationMiddle Agedmedicine.diseasehumanitiesStrokeNeurologyQuality of LifeGeriatric Depression ScaleAnticonvulsantsFemaleNeurology (clinical)business030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Association of prestroke metformin use, stroke severity, and thrombolysis outcome

2020

ObjectiveTo evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.MethodsData from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.ResultsOf 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+),…

Malemedicine.medical_specialtymedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic AgentsThrombolytic Therapycardiovascular diseases10064 Neuroscience Center ZurichStrokeAgedRetrospective Studiesbusiness.industryRecovery of Function10060 Epidemiology Biostatistics and Prevention Institute (EBPI)ThrombolysisMiddle Agedmedicine.diseaseMetformin10040 Clinic for Neurology3. Good healthMetforminStroke2728 Neurology (clinical)Diabetes Mellitus Type 2Propensity score matchingCohortFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology
researchProduct